Howard Kaufman
Howard Kaufman
Professor, Rutgers University
Verified email at
Cited by
Cited by
Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
RHI Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ...
Journal of clinical oncology 33 (25), 2780-2788, 2015
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I Puzanov, A Diab, K Abdallah, CO Bingham, C Brogdon, R Dadu, ...
Journal for immunotherapy of cancer 5 (1), 1-28, 2017
Oncolytic viruses: a new class of immunotherapy drugs
HL Kaufman, FJ Kohlhapp, A Zloza
Nature reviews Drug discovery 14 (9), 642-662, 2015
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
HL Kaufman, J Russell, O Hamid, S Bhatia, P Terheyden, SP D'Angelo, ...
The lancet oncology 17 (10), 1374-1385, 2016
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
DJ Schwartzentruber, DH Lawson, JM Richards, RM Conry, DM Miller, ...
New England Journal of Medicine 364 (22), 2119-2127, 2011
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma
NN Senzer, HL Kaufman, T Amatruda, M Nemunaitis, T Reid, G Daniels, ...
Journal of Clinical Oncology 27 (34), 5763, 2009
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ...
JAMA oncology 2 (2), 234-240, 2016
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
HL Kaufman, DW Kim, G DeRaffele, J Mitcham, RS Coffin, S Kim-Schulze
Annals of surgical oncology 17, 718-730, 2010
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ...
Journal for immunotherapy of cancer 8 (1), 2020
Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with …
J Chesney, I Puzanov, F Collichio, P Singh, MM Milhem, J Glaspy, ...
Journal of clinical oncology 36 (17), 1658, 2018
Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma
I Puzanov, MM Milhem, D Minor, O Hamid, A Li, L Chen, M Chastain, ...
Journal of Clinical Oncology 34 (22), 2619, 2016
Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma
GC Cesana, G DeRaffele, S Cohen, D Moroziewicz, J Mitcham, ...
Journal of Clinical Oncology 24 (7), 1169-1177, 2006
Integrating oncolytic viruses in combination cancer immunotherapy
PK Bommareddy, M Shettigar, HL Kaufman
Nature Reviews Immunology 18 (8), 498-513, 2018
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7. 1 co-stimulatory molecule
H Hörig, DS Lee, W Conkright, J Divito, H Hasson, M LaMare, A Rivera, ...
Cancer Immunology, Immunotherapy 49, 504-514, 2000
Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial
SP D’Angelo, J Russell, C Lebbé, B Chmielowski, T Gambichler, JJ Grob, ...
JAMA oncology 4 (9), e180077-e180077, 2018
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
JM Mehnert, A Panda, H Zhong, K Hirshfield, S Damare, K Lane, L Sokol, ...
The Journal of clinical investigation 126 (6), 2334-2340, 2016
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction
W Zhang, Y Yu, F Hertwig, J Thierry-Mieg, W Zhang, D Thierry-Mieg, ...
Genome biology 16 (1), 1-12, 2015
Combination immunotherapy: a road map
PA Ott, FS Hodi, HL Kaufman, JM Wigginton, JD Wolchok
Journal for immunotherapy of cancer 5, 1-15, 2017
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
H Rehman, AW Silk, MP Kane, HL Kaufman
Journal for immunotherapy of cancer 4, 1-8, 2016
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
HL Kaufman, W Wang, J Manola, RS DiPaola, YJ Ko, C Sweeney, ...
Journal of Clinical Oncology 22 (11), 2122-2132, 2004
The system can't perform the operation now. Try again later.
Articles 1–20